Influence of clinical trial site enrollment on patient characteristics, protocol completion, and end points

Circulation: Heart Failure

Volumn 9, Issue 9, 2016, Pages

  Greene, Stephen J ^a   Hernandez, Adrian F ^a,b   Sun, Jie Lena ^b   Metra, Marco ^c   Butler, Javed ^d   Ambrosy, Andrew P ^a,b   Ezekowitz, Justin A ^e   Starling, Randall C ^f   Teerlink, John R ^g   Schulte, Phillip J ^b   Voors, Adriaan A ^h   Armstrong, Paul W ^e   O'Connor, Christopher M ^a,b   Mentz, Robert J ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

clinical trial; heart failure; patient discharge; quality of life

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DEATH; DYSPNEA; FEMALE; HEART EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STUDY DESIGN; BIOASSAY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CONVALESCENCE; DISEASE COURSE; HEART FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PATIENT DROPOUT; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DYSPNEA; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PATIENT DROPOUTS; PATIENT READMISSION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84988557183     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.002986     Document Type: Article

References (23)

1. Braunwald E, Heart failure. JACC Heart Fail 2013 1 1 20. doi: 10.1016/j.jchf.2012.10.002
2. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC, OPTIMIZE-HF Investigators and Coordinators Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006 296 2217 2226. doi: 10.1001/jama.296.18.2217
3. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007 297 1319 1331. doi: 10.1001/jama.297.12.1319
4. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC, PROTECT Investigators and Committees Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010 363 1419 1428. doi: 10.1056/NEJMoa0912613
5. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM, Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011 365 32 43. doi: 10.1056/NEJMoa1100171
6. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP, ASTRONAUT Investigators and Coordinators Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013 309 1125 1135. doi: 10.1001/jama.2013.1954
7. Gheorghiade M, Vaduganathan M, Greene SJ, Mentz RJ, Adams KF Jr, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, Nodari S, Frank Peacock W, Pieske BM, Sabbah HN, Sato N, Shah MR, Stockbridge NL, Teerlink JR, van Veldhuisen DJ, Zalewski A, Zannad F, Butler J, Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev 2014 19 135 152. doi: 10.1007/s10741-012-9361-8
8. Butler J, Fonarow GC, O'Connor C, Adams K, Bonow RO, Cody RJ, Collins SP, Dunnmon P, Dinh W, Fiuzat M, Georgiopoulou VV, Grant S, Kim SY, Kupfer S, Lefkowitz M, Mentz RJ, Misselwitz F, Pitt B, Roessig L, Schelbert E, Shah M, Solomon S, Stockbridge N, Yancy C, Gheorghiade M, Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J 2015 169 305 314. doi: 10.1016/j.ahj.2014.12.001
9. Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Dunnmon PM, Fonarow GC, Lam CS, Mentz RJ, Pieske B, Roessig L, Rosano GM, Sato N, Vaduganathan M, Gheorghiade M, Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J 2014 168 142 149. doi: 10.1016/j.ahj.2014.05.009
10. Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M, EVEREST Investigators Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol 2013 61 571 579. doi: 10.1016/j.jacc.2012.10.025
11. Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL, STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol 2010 56 490 498. doi: 10.1016/j.jacc.2009.11.102
12. Mentz RJ, Cotter G, Cleland JG, Stevens SR, Chiswell K, Davison BA, Teerlink JR, Metra M, Voors AA, Grinfeld L, Ruda M, Mareev V, Lotan C, Bloomfield DM, Fiuzat M, Givertz MM, Ponikowski P, Massie BM, O'Connor CM, International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014 16 614 624. doi: 10.1002/ejhf.92
13. Greene SJ, Fonarow GC, Solomon SD, Subacius H, Maggioni AP, Böhm M, Lewis EF, Zannad F, Gheorghiade M, ASTRONAUT Investigators and Coordinators Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. Eur J Heart Fail 2015 17 591 600. doi: 10.1002/ejhf.280
14. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM, Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009 157 271 277. doi: 10.1016/j.ahj.2008.07.031
15. Khazanie P, Heizer GM, Hasselblad V, Armstrong PW, Califf RM, Ezekowitz J, Dickstein K, Levy WC, McMurray JJ, Metra M, Tang WH, Teerlink JR, Voors AA, O'Connor CM, Hernandez AF, Starling R, Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. Am Heart J 2015 170 290 297. doi: 10.1016/j.ahj.2015.04.006
16. Mentz RJ, Hernandez AF, Stebbins A, Ezekowitz JA, Felker GM, Heizer GM, Atar D, Teerlink JR, Califf RM, Massie BM, Hasselblad V, Starling RC, O'Connor CM, Ponikowski P, Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 2013 15 456 464. doi: 10.1093/eurjhf/hfs188
17. Gheorghiade M, Ruschitzka F, Beyond dyspnoea as an endpoint in acute heart failure trials. Eur Heart J 2011 32 1442 1445. doi: 10.1093/eurheartj/ehr044
18. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M, Acute Heart Failure Syndromes International Working Group A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008 29 816 824. doi: 10.1093/eurheartj/ehn048
19. Ferreira JP, Girerd N, Rossignol P, Zannad F, Geographic differences in heart failure trials. Eur J Heart Fail 2015 17 893 905. doi: 10.1002/ejhf.326
20. Greene SJ, Gheorghiade M, Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? Eur J Heart Fail 2015 17 875 878. doi: 10.1002/ejhf.335
21. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J, The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 2013 10 85 97. doi: 10.1038/nrcardio.2012.181
22. Shah SJ, Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter. J Am Coll Cardiol 2013 62 1339 1342. doi: 10.1016/j.jacc.2013.07.010
23. Eapen ZJ, Lauer MS, Temple RJ, The imperative of overcoming barriers to the conduct of large, simple trials. JAMA 2014 311 1397 1398. doi: 10.1001/jama.2014.1030